Plato Investment Management Ltd Has $1.37 Million Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Plato Investment Management Ltd increased its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 69.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,944 shares of the medical research company’s stock after acquiring an additional 2,836 shares during the quarter. Plato Investment Management Ltd’s holdings in IQVIA were worth $1,370,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Capital Performance Advisors LLP acquired a new position in shares of IQVIA during the third quarter valued at $27,000. Avior Wealth Management LLC lifted its stake in shares of IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after acquiring an additional 87 shares during the period. Synergy Asset Management LLC acquired a new position in shares of IQVIA during the fourth quarter valued at $33,000. Assetmark Inc. lifted its stake in shares of IQVIA by 612.5% during the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after acquiring an additional 196 shares during the period. Finally, Ashton Thomas Securities LLC acquired a new position in IQVIA in the third quarter valued at about $57,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Down 2.2 %

NYSE:IQV opened at $184.67 on Tuesday. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The company has a market cap of $32.52 billion, a PE ratio of 24.62, a PEG ratio of 1.99 and a beta of 1.48. IQVIA Holdings Inc. has a 52-week low of $184.06 and a 52-week high of $261.73. The stock has a 50-day simple moving average of $198.84 and a 200 day simple moving average of $214.25.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analysts Set New Price Targets

IQV has been the topic of several analyst reports. BTIG Research lowered IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. Royal Bank of Canada reissued an “outperform” rating and issued a $270.00 target price on shares of IQVIA in a research note on Monday, February 10th. Leerink Partners reissued an “outperform” rating and issued a $248.00 target price (down previously from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. JPMorgan Chase & Co. cut their target price on IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 18th. Finally, Barclays cut their target price on IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a research note on Monday, February 3rd. Four equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and an average target price of $251.22.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.